rheumatoid%20arthritis
RHEUMATOID ARTHRITIS

Rheumatoid arthritis is a systemic autoimmune rheumatic disorder of unknown etiology.
It is the most common form of inflammatory arthritis.
Patient usually complains of joint pain and/or swelling with morning stiffness that lasts for more than an hour.

Goals of treatment are clinical & radiological remission of disease and to reduce functional limitations & permanent joint damage.

Follow Up

Monitoring for Drug Toxicity

  • Eg complete blood count, serum creatinine, liver function tests, hepatitis B & C screening, ophthalmologic exam, latent tuberculosis screening (for biological DMARDs, with chest X-ray)
  • Recommended prior to resuming or increasing therapy with DMARDs
  • It is important to monitor for toxicity due to the potential risks of serious adverse effects of DMARDs

Tapering of Therapy

  • Should be considered if there is disease remission with biological DMARDs therapy of at least 6 months
    • Glucocorticoid dose should be tapered first prior to reduction of dose of biological DMARDs
  • To decrease risk of flares, gradual withdrawal of biological therapies should be done
    • Flare risk is inversely proportional to disease activity & sustained response duration
  • In persistent remission of at least 12 months, biological DMARDs should be slowly tapered by expanding the interval between doses or dose reduction, while continuing non-biological DMARDs
  • Ceasing treatment with non-biological DMARDs is associated with increased flare frequency, hence tapering should be done cautiously & should be evaluated rigorously

Disease Activity Monitoring

  • Disease activity should be measured & documented regularly
    • Moderate-high disease activity: monthly
    • Sustained low disease activity: every 6 months
    • Clinical remission: every 6 months (with DAS & DAS28)
    • Sustained remission: every 3-6 months
  • Consider structural changes, comorbidities, & functional impairment when formulating treatment decisions on follow-ups
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Use of potassium citrate and thiazides appears to improve health-related quality of life (HRQOL) among stone formers across all Wisconsin Stone Quality of Life (WISQOL) domains without increasing the likelihood of gastrointestinal complaints and fatigue or sexual complaints, respectively, reports a study.
Pearl Toh, 6 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
3 days ago
Eating high amounts of red and processed meat prior to a diagnosis of colorectal cancer appears to be associated with shorter survival time, although a possible weak association cannot be excluded, a study has shown.
3 days ago
Middle-aged Caucasian men who are dissatisfied with their marriage are at higher risk of sudden cardiac death regardless of other cardiovascular risk factors, a new study reports.